If you are interested in the 2025 Event, please get in touch:
Unravelling DDR Networks by Identifying Novel Targets, Developing Rational Combinations and Improving Biomarker-Lead Clinical Stratification, to Exploit Synthetic Lethality and Deliver Safe
DDR Inhibitors to Patients
The 7th DDR Inhibitors Summit
What the 2024 Summit Uncovered:
DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like Roche and Gilead are diving into this therapeutic strategy; biotech companies like Artios and IDEAYA remain dedicated to
delivering safe and effective treatments to patients.
The unmet need for cancer therapies reinforces the critical importance for the community that united at the
7th Annual DDR Inhibitors Summit in Boston, January 2024, to advance first-in-class oncology treatments for patients.
This year’s conference underwent a renovation to maximize your experience, featuring a new biomarkers pre-conference focus day with the goal of demystifying patient stratification and target ID. Two tracks for the main conference days followed, covering early discovery of next-generation targets and clinical updates.
100 peers in oncology innovation, synthetic lethality, medicinal chemistry, and clinical development, joined together at the exclusive DDR Inhibitors conference - the sole industry-led event providing unmatched depth and insight into your challenges.
World-Class Speaker Faculty Included:
Snapshot of Previously Attending Companies:
“It was very interactive with many people with different expertise (basic and translational science, clinical, biomarkers, etc.) asking excellent questions of the presenters and panellists.” - Director – Oncology Translation & Biomarker Research, EMD Serano
“The DDR summit is as usual the place to be for people working in the field of DDR therapeutics, but not only. I enjoyed the quality of speakers and the round tables!” - Head of In Vitro Oncology Research & Innovation, Onxeo